Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16306938 | 0.90 | LMNA (0.58) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 | |
| SCHEMBL667434 | 0.90 | MEN1 (0.48) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 | |
| SCHEMBL9848816 | 0.90 | CYP26A1 (0.60) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 | |
| SCHEMBL1374453 | 0.90 | CYP26A1 (0.60) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 | |
| SCHEMBL16199337 | 0.90 | CYP26A1 (0.60) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 | |
| SCHEMBL9848801 | 0.87 | MAPT (0.54) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 | |
| SCHEMBL6676599 | 0.87 | MAPT (0.51) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 | |
| SCHEMBL31226878 | 0.87 | MAPT (0.54) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 | |
| SCHEMBL9848805 | 0.87 | MAPT (0.54) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 | |
| SCHEMBL9848797 | 0.87 | MAPT (0.54) | CYP26A1MAPTSMN1; SMN2ALOX5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-9040560-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| EP-2396307-B1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2014-10-15 | — | — | EP | disclosed |
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-8637532-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| CN-102317269-A | Novel amino aza heterocyclic carboxamides | MERCK PATENT GMBH | 2012-01-11 | — | — | CN | disclosed |
| EP-2396307-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093419-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2010-08-19 | — | — | WO | disclosed |
| US-5378838-A | FOR USE IN HUMANS | MERCK & CO., INC. (US) | 1995-01-03 | — | — | US | disclosed |
| WO-1994015924-A1 | CHOLECYSTOKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| US-5280027-A | Quinazoline containing compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107156-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | CYP26A1 2307/4885MAPT 4799/4885SMN1; SMN2 3093/4885 |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | CYP26A1 2307/4885MAPT 4799/4885SMN1; SMN2 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.